ReesFDohertyMGraingeMDavenportGLanyonPZhangW. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012. Ann Rheum Dis2016; 75: 136–141.
2.
JohnsonAEGordonCPalmerRGBaconPA. The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Arthritis & Rheumatism1995; 38: 551–558.
3.
MorganCBlandARMakerCDunnageJBruceIN. Individuals living with lupus: findings from the LUPUS UK Members Survey 2014. Lupus2018; 27: 681–687.
4.
GordonCAmissah-ArthurM-BGayedMet al.The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology2018; 57: e1–e45.
5.
BertsiasGIoannidisJPBoletisJet al.EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis2008; 67: 195–205.
6.
BermasBLKimSCHuybrechtsKet al.Trends in use of hydroxychloroquine during pregnancy in systemic lupus erythematosus patients from 2001 to 2015. Lupus2018. 27: 1012--1017.
7.
FlintJPanchalSHurrellAet al.BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding—Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatology2016; 55: 1693–1697.
8.
RahmanAIsenbergDA. Systemic Lupus Erythematosus. New England Journal of Medicine2008; 358: 929–939.
9.
LedinghamJGullickNIrvingKet al.BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs. Rheumatology2017; 56: 865–868.
10.
RahmanPHumphrey-MurtoSGladmanDDUrowitzMB. Cytotoxic therapy in systemic lupus erythematosus. Experience from a single center. Medicine (Baltimore)1997; 76: 432–437.
